Xarelto Declines Are New Normal At Bayer
Sales Of Biggest Earner Slip In Q1
Sales of the blockbuster Factor Xa blood thinner Xarelto declined more steeply than was expected but Bayer’s second biggest seller Eylea is still performing well.
You may also be interested in...
Bayer Saddles Up For Bicycle Radioconjugate Pact
The German major is paying $45m upfront to get access to Bicycle’s synthetic peptides for the discovery and development of multiple targeted radioconjugates in oncology.
Five Challenges Bill Anderson Faces At Bayer
Six weeks after leaving Roche, Bill Anderson is taking the helm at Bayer in one of the most intriguing appointments in the sector for some time.
Bullish Bayer Highlights Four Future Blockbusters
The German group has shone a light at the J.P. Morgan Healthcare Conference on its new launched drugs Nubeqa and Kerendia, plus its late-stage candidates asundexian and elinzanetant, as it prepares for life after patent expiries on Xarelto and Eylea.